Key Takeaway: The article discusses a presentation by Lizama et al. at the Society for Neuroscience annual meeting in November 2023. The research focuses on the unbiased proteomic and transcriptomic analysis of Sigma-2 receptor modulation in an in vivo model of synucleinopathy. This study may contribute to the understanding of synucleinopathy and its underlying mechanisms.
Price reaction · baseline $1 (2023-11-09 close) · hit pre-market · 3 other CGTX headline(s) in the window, move may be shared
day 0 close · peak
+6.5%
day 1
+3%
day 3
+5%
Market Sentiment Analysis
POSITIVE FACTORS
Presentation at a prestigious annual meeting
Focus on innovative proteomic and transcriptomic analysis
Potential implications for understanding synucleinopathy
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
Lizama BN, Reaver AJ, Pandey K, et al. Unbiased proteomic and transcriptomic analysis of Sigma-2 receptor modulation in an in vivo model of synucleinopathy . Poster presented Nov 2023 at: Society for Neuroscience (SfN) annual meeting ; Washington DC.
Frequently Asked Questions
What was presented at the Society for Neuroscience meeting?
The presentation focused on Sigma-2 receptor modulation in synucleinopathy.
Who conducted the research on Sigma-2 receptors?
The research was conducted by Lizama BN, Reaver AJ, Pandey K, and others.
What type of analysis was used in the study?
The study utilized unbiased proteomic and transcriptomic analysis.